Johnson & Johnson vs ON Holding AG — how do they compare? Johnson & Johnson trades at $249.4 (market cap $598.96B), while ON Holding AG trades at $37.17 (market cap $12.55B). The key difference: Johnson & Johnson is far larger — about 47.7× ON Holding AG's market cap, and Johnson & Johnson pays a 2.15% dividend while ON Holding AG pays none. Which is the better fit depends on your goals.
| JNJ | ONON | |
|---|---|---|
Market Cap | $598.96B | $12.55B |
Volume | 6,156,228 | — |
Sector | Health | Technology |
52-Week High | $267.24 | $53.21 |
52-Week Low | $164.36 | $31.88 |
Enterprise Value | $631.90B | $11.87B |
Dividend Yield | 2.15% | — |
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
ONON trades at $37.65, up 1.21% today, with a bearish technical signal from moving averages but neutral oscillators. The company shows strong profitability with a 63.88% gross margin and has beaten earnings estimates for three consecutive quarters. Revenue reached $3.01B in 2025, with net income of $203.70M. Analyst sentiment is overwhelmingly positive, with 76.92% recommending Buy.
The outlook remains favorable due to consistent earnings beats and projected revenue growth to $3.1B in 2026. Risks include high valuation multiples like a P/E of 40.14 and competitive pressures. The consensus price target of $47.33 suggests 25.7% upside, but investors should monitor execution against growth expectations.
Trailing returns across standard periods
Latest headlines on both assets
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →ON Holding AG is a Swiss sports company primarily known for its high-performance running shoes, apparel, and accessories under the 'On' brand. The company emphasizes a blend of high-end design, proprietary cloud technology (like CloudTec cushioning), and sustainability in its products. On has rapidly gained market share globally, appealing to both competitive athletes and general consumers in the performance and lifestyle footwear segments.
Read more on ONON →